Entresto 200 Mg 56 Tablets

Entresto 200 Mg 56 Tablets

Description:

Entresto 200 mg (97/103 mg) film-coated tablets is a prescription cardiovascular medicine used in the long-term management of chronic heart failure with reduced ejection fraction. It contains the fixed-dose combination of sacubitril and valsartan, known as an angiotensin receptor neprilysin inhibitor (ARNI), and is indicated to reduce the risk of cardiovascular death and heart failure hospitalizations in adult patients with chronic heart failure (NYHA class II–IV). Entresto is not a vitamin or dietary supplement; it is a potent prescription-only medicine that must be used under the supervision of a cardiologist or qualified healthcare professional.

Indications:

• Chronic heart failure (CHF) with reduced ejection fraction (HFrEF) in adults, NYHA class II–IV.
• Reduction of risk of cardiovascular death in patients with symptomatic chronic heart failure.
• Reduction of hospitalizations due to worsening heart failure.
• Management of symptoms associated with heart failure such as shortness of breath, fatigue, and exercise intolerance, as part of a comprehensive heart failure treatment plan.

Active Ingredients / Key Components:

• Sacubitril – 97 mg per tablet (as sacubitril/valsartan sodium salt complex).
• Valsartan – 103 mg per tablet.
• Total strength: Entresto 200 mg (97/103 mg) film-coated tablet.
• Inactive ingredients/excipients: Full excipient list is not available in this description; please refer to the official package leaflet for complete information.

Dosage & Administration / How to Use:

• Entresto 200 mg (97/103 mg) tablets are typically used as the target maintenance dose after titration from lower strengths (e.g., 49 mg/51 mg twice daily), as tolerated.
• Usual adult maintenance dose: 97 mg sacubitril / 103 mg valsartan (one 200 mg tablet) taken orally twice daily, as prescribed by a cardiologist.
• Initiation: Recommended starting dose in most patients is 49 mg/51 mg twice daily, then increased after 2–4 weeks to 97 mg/103 mg twice daily if tolerated. Do not start directly at 200 mg unless specifically directed by your physician.
• With or without food: Tablets may be taken with or without food, but should be taken consistently the same way each day.
• Swallow whole: Swallow the tablet whole with a glass of water; do not crush or chew unless advised otherwise by your doctor.
• ACE inhibitor washout: If switching from an ACE inhibitor, a washout period of at least 36 hours is required before starting Entresto to reduce risk of angioedema.
• Missed dose: If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed dose.
• Renal or hepatic impairment, elderly, or low blood pressure: Dose adjustments and slower titration may be required. Follow your doctor’s instructions strictly.
• Use only under regular medical supervision, with periodic monitoring of blood pressure, kidney function, and blood potassium levels.

Clinical Benefits:

• Helps significantly reduce the risk of cardiovascular death in patients with chronic heart failure and reduced ejection fraction.
• Lowers the risk of hospitalization due to worsening heart failure when used as part of guideline-directed medical therapy.
• Improves heart failure symptoms such as breathlessness, fatigue, and reduced exercise capacity in many patients.
• Supports better long-term management of chronic heart failure by combining neprilysin inhibition and angiotensin II receptor blockade in a single tablet.
• Contributes to improved quality of life and functional status in eligible heart failure patients when used regularly and as prescribed.

Warnings & Contraindications:

• Entresto is a prescription-only medicine and must be used strictly under medical supervision.
• Contraindications: History of angioedema related to previous ACE inhibitor or ARB therapy; hereditary or idiopathic angioedema; concomitant use with ACE inhibitors; concomitant use with aliskiren in patients with diabetes; pregnancy; known hypersensitivity to sacubitril, valsartan, or any excipient.
• May cause symptomatic hypotension (low blood pressure), especially in patients who are volume-depleted, on high-dose diuretics, or elderly.
• Can affect kidney function and increase serum potassium; caution in patients with renal impairment or those taking potassium-sparing diuretics, potassium supplements, or other medicines that increase potassium.
• Not recommended in severe hepatic impairment; dose adjustment may be required in mild to moderate hepatic impairment.
• Do not use during pregnancy; medicines acting on the renin-angiotensin system can cause injury and death to the developing fetus. If pregnancy is detected, discontinue Entresto as soon as possible.
• Breastfeeding: Use is generally not recommended; consult your doctor to weigh risks and benefits.
• May interact with ACE inhibitors, ARBs, aliskiren, diuretics, NSAIDs, lithium, and other antihypertensives. Inform your doctor about all medicines and supplements you are taking.
• Use with caution in patients with a history of angioedema, severe aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as kidney disease, liver disease, low blood pressure, or high potassium levels.
• Keep out of reach of children.

Side Effects:

• Common side effects: Low blood pressure (dizziness, lightheadedness, fainting), increased blood potassium (hyperkalemia), kidney function changes, cough, fatigue, headache, and gastrointestinal discomfort.
• Serious side effects: Angioedema (swelling of face, lips, tongue, or throat; difficulty breathing or swallowing), severe hypotension, severe kidney impairment, or dangerously high potassium levels. These require immediate medical attention.
• If you experience swelling of the face, lips, tongue, or throat, sudden difficulty breathing, severe dizziness, or fainting, stop taking the medicine and seek emergency medical help immediately.
• Always report any unusual or persistent symptoms to your doctor, especially if you have underlying kidney disease or are on multiple heart medications.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date stated on the pack. Store at or below the temperature recommended on the original packaging (refer to the leaflet or outer carton for exact storage conditions).

Specifications:

• Product type: Prescription cardiovascular medicine for chronic heart failure.
• Strength: 200 mg total per film-coated tablet (97 mg sacubitril / 103 mg valsartan).
• Form: Film-coated tablet.
• Pack size: 56 tablets per pack.
• Route of administration: Oral.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.